EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Abstract 4573: Angiotensinogen-Targeting RNA Interference with Zilebesiran for Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials

Jay Gohri, Aniroodh Venugopalan, Prakhar Gupta, Aparna Sajja, Kunal K Bhatt

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.4573 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Jay Gohri und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poor blood pressure control remains a major contributor to cardiovascular morbidity and mortality. Zilebesiran, a hepatocyte-targeted small interfering RNA that suppresses angiotensinogen synthesis, offers prolonged blood pressure lowering with infrequent dosing and may address adherence-related limitations of conventional therapy.

Methods

We conducted a systematic review and meta-analysis of randomized trials evaluating zilebesiran in adults with hypertension. Databases and trial registries were searched from inception through April 2026. The primary endpoint was change from baseline in 24-hour ambulatory systolic blood pressure at approximately 3 months. A random-effects generic inverse-variance model was used to pool least-squares mean differences. Prespecified subgroup analyses examined background antihypertensive therapy and degree of heterogeneity among study results were assessed using I-square statistic.

Results

Six randomized comparisons from phase 2 studies were included. Zilebesiran significantly reduced 24-hour ambulatory systolic blood pressure versus placebo or standard therapy, with a pooled mean difference of -11.92 mm Hg (95% CI -15.68 to -8.17; p < 0.001). Heterogeneity was substantial (I 2 = 78.9%), largely driven by background therapy. The effect was greatest in monotherapy cohorts, where the pooled reduction was -15.61 mm Hg (95% CI -18.41 to -12.81; I 2 = 0%). Add-on therapy also demonstrated benefit, though attenuated, with reductions of -12.10 mm Hg with indapamide, -9.70 mm Hg with amlodipine, and -4.50 mm Hg with olmesartan. All comparisons favored zilebesiran. Short-term safety was acceptable, with no consistent signal for serious renal events, hyperkalemia, or severe hypotension. Further, the subgroup differences are highly significant (χ 2 = 23.12, df = 3, p < 0.0001), indicating that treatment effects differ meaningfully across subgroups (monotherapy, indapamide, amlodipine, olmesartan). This supports the conclusion that concomitant antihypertensive therapy modifies the efficacy of zilebesiran.

Conclusions

In randomized phase 2 trials, zilebesiran produced clinically meaningful and sustained reductions in ambulatory blood pressure, particularly as monotherapy, with a favorable short-term safety profile. These findings support AGT-targeting RNA interference as a promising long-acting strategy for hypertension and justify ongoing phase 3 outcome evaluation.

Zitieren

APA

Gohri, J., Venugopalan, A., Gupta, P., Sajja, A., & Bhatt, K. K. (2026). Abstract 4573: Angiotensinogen-Targeting RNA Interference with Zilebesiran for Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.4573

Vancouver

Gohri J, Venugopalan A, Gupta P, Sajja A, Bhatt KK. Abstract 4573: Angiotensinogen-Targeting RNA Interference with Zilebesiran for Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.4573

BibTeX
@article{Gohri2026,
  author = {Gohri, Jay and Venugopalan, Aniroodh and Gupta, Prakhar and Sajja, Aparna and Bhatt, Kunal K},
  title = {Abstract 4573: Angiotensinogen-Targeting RNA Interference with Zilebesiran for Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.4573}
}
Kostenlos starten →